Back to search

Article

Asprosin Neutralizing Antibodies as a Treatment for Metabolic Syndrome

2020-09-16

Abstract excerpt

Recently, we discovered a new glucogenic and centrally-acting orexigenic hormone – asprosin. Asprosin is elevated in metabolic syndrome (MS) patients, and importantly, its genetic loss results in reduced appetite, leanness and robust insulin sensitivity, leading to protection from MS. Here we demonstrate that anti-asprosin monoclonal antibodies (mAbs) are a dual-effect pharmacologic therapy that targets the two ke...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c9bfaed2-2125-5be7-b305-3d13601ae0df
DOI
10.1101/2020.09.15.298489
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Asprosin Neutralizing Antibodies as a Treatment for Metabolic SyndromeDOI 10.1101/2020.09.15.298489
Select a neighboring publication to make it the new centre.